Oramed Pharmaceuticals Inc. — Director's Dealing 2022

Aug 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2022-07-28

Reporting Person: Sank Leonard (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-28	Common Stock	A	12000	—	Acquired	18000	Direct

Footnotes

F1: Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 4,000 shall vest on each of January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

F2: The reporting person previously reported and disclaimed beneficial ownership over 138,889 shares of common stock owned by a company wholly owned by a trust of which the reporting person was previously a trustee. The reporting person resigned as a trustee of such trust, effective February 3, 2022.